Report cover image

Anti-Tumor Drugs Market by Indications (Breast Cancer, Leukemia, Lung Cancer), Route of Administration (Intra-muscular, Intraperitoneal, Intravenous), Drug Class, Distribution Channels, End User - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 192 Pages
SKU # IRE18418380

Description

Anti-Tumor Drugs Market by Indications (Breast Cancer, Leukemia, Lung Cancer), Route of Administration (Intra-muscular, Intraperitoneal, Intravenous), Drug Class, Distribution Channels, End User - Global Forecast 2024-2030


The Anti-Tumor Drugs Market size was estimated at USD 34.89 billion in 2023 and expected to reach USD 39.14 billion in 2024, at a CAGR 12.24% to reach USD 78.35 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-Tumor Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Tumor Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-Tumor Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cybrexa Therapeutics, Dr. Reddy’s Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Getwell Oncology, GLS Pharma Pvt. Ltd., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., PharmaMar, Sanofi SA, Taiho Oncology, Inc, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Anti-Tumor Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Indications

Breast Cancer
  • Leukemia
  • Lung Cancer
  • Melanoma
  • Prostate Cancer
  • Route of Administration

    Intra-muscular
  • Intraperitoneal
  • Intravenous
  • Intraventricular or Intrathecal
  • Intravesicular
  • Oral
  • Subcutaneous
  • Topical
  • Drug Class

    Cytotoxics
  • Hormonal Therapy
  • Targeted Therapy

    Monoclonal Antibodies
  • Small Molecule Inhibitors
  • Distribution Channels

    Hospital Pharmacies
  • Retail Pharmacies
  • End User

    Clinics
  • Hospitals
  • Specialty Centers
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Anti-Tumor Drugs Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Tumor Drugs Market?
    3. What are the technology trends and regulatory frameworks in the Anti-Tumor Drugs Market?
    4. What is the market share of the leading vendors in the Anti-Tumor Drugs Market?
    5. Which modes and strategic moves are suitable for entering the Anti-Tumor Drugs Market?


    Note: PDF & Excel + Online Access - 1 Year

    • Table of Contents

    192 Pages
    1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Anti-Tumor Drugs Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Rise in incidence of cancer with the surge in the geriatric population
    5.1.1.2. Growing awareness regarding early diagnosis and treatment for the cancer
    5.1.1.3. Increase in expenditures on healthcare by government
    5.1.2. Restraints
    5.1.2.1. High cost of anticancer drugs and low survival rate
    5.1.3. Opportunities
    5.1.3.1. Availability of pipelined drugs and upsurge in demand for personalized medicines for the tumor treatment
    5.1.3.2. Recent innovations in anticancer therapies
    5.1.4. Challenges
    5.1.4.1. Unfavorable outcomes associated with the use of cancer drugs
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Anti-Tumor Drugs Market, by Indications
    6.1. Introduction
    6.2. Breast Cancer
    6.3. Leukemia
    6.4. Lung Cancer
    6.5. Melanoma
    6.6. Prostate Cancer
    7. Anti-Tumor Drugs Market, by Route of Administration
    7.1. Introduction
    7.2. Intra-muscular
    7.3. Intraperitoneal
    7.4. Intravenous
    7.5. Intraventricular or Intrathecal
    7.6. Intravesicular
    7.7. Oral
    7.8. Subcutaneous
    7.9. Topical
    8. Anti-Tumor Drugs Market, by Drug Class
    8.1. Introduction
    8.2. Cytotoxics
    8.3. Hormonal Therapy
    8.4. Targeted Therapy
    8.5.1. Monoclonal Antibodies
    8.5.2. Small Molecule Inhibitors
    9. Anti-Tumor Drugs Market, by Distribution Channels
    9.1. Introduction
    9.2. Hospital Pharmacies
    9.3. Retail Pharmacies
    10. Anti-Tumor Drugs Market, by End User
    10.1. Introduction
    10.2. Clinics
    10.3. Hospitals
    10.4. Specialty Centers
    11. Americas Anti-Tumor Drugs Market
    11.1. Introduction
    11.2. Argentina
    11.3. Brazil
    11.4. Canada
    11.5. Mexico
    11.6. United States
    12. Asia-Pacific Anti-Tumor Drugs Market
    12.1. Introduction
    12.2. Australia
    12.3. China
    12.4. India
    12.5. Indonesia
    12.6. Japan
    12.7. Malaysia
    12.8. Philippines
    12.9. Singapore
    12.10. South Korea
    12.11. Taiwan
    12.12. Thailand
    12.13. Vietnam
    13. Europe, Middle East & Africa Anti-Tumor Drugs Market
    13.1. Introduction
    13.2. Denmark
    13.3. Egypt
    13.4. Finland
    13.5. France
    13.6. Germany
    13.7. Israel
    13.8. Italy
    13.9. Netherlands
    13.10. Nigeria
    13.11. Norway
    13.12. Poland
    13.13. Qatar
    13.14. Russia
    13.15. Saudi Arabia
    13.16. South Africa
    13.17. Spain
    13.18. Sweden
    13.19. Switzerland
    13.20. Turkey
    13.21. United Arab Emirates
    13.22. United Kingdom
    14. Competitive Landscape
    14.1. FPNV Positioning Matrix
    14.2. Market Share Analysis, By Key Player
    14.3. Competitive Scenario Analysis, By Key Player
    15. Competitive Portfolio
    15.1. Key Company Profiles
    15.1.1. AbbVie Inc.
    15.1.2. Amgen inc.
    15.1.3. Astellas Pharma Inc.
    15.1.4. AstraZeneca PLC
    15.1.5. Bayer AG
    15.1.6. Biogen Inc.
    15.1.7. Bristol-Myers Squibb Company
    15.1.8. Celgene Corporation
    15.1.9. Cybrexa Therapeutics
    15.1.10. Dr. Reddy’s Laboratories Ltd.
    15.1.11. Eisai Co., Ltd.
    15.1.12. Eli Lilly and Company
    15.1.13. F. Hoffmann-La Roche Ltd
    15.1.14. Genentech, Inc.
    15.1.15. Getwell Oncology
    15.1.16. GLS Pharma Pvt. Ltd.
    15.1.17. Merck & Co., Inc.
    15.1.18. Novartis AG
    15.1.19. Otsuka Pharmaceutical Co., Ltd
    15.1.20. Pfizer Inc.
    15.1.21. PharmaMar
    15.1.22. Sanofi SA
    15.1.23. Taiho Oncology, Inc
    15.1.24. Takeda Pharmaceutical Company Limited
    15.1.25. Teva Pharmaceutical Industries Ltd.
    15.2. Key Product Portfolio
    16. Appendix
    16.1. Discussion Guide
    16.2. License & Pricing
    FIGURE 1. ANTI-TUMOR DRUGS MARKET RESEARCH PROCESS
    FIGURE 2. ANTI-TUMOR DRUGS MARKET SIZE, 2023 VS 2030
    FIGURE 3. ANTI-TUMOR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ANTI-TUMOR DRUGS MARKET DYNAMICS
    FIGURE 7. ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
    FIGURE 8. ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
    FIGURE 10. ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
    FIGURE 12. ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
    FIGURE 14. ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
    FIGURE 16. ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 20. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 22. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 25. ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 26. ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2023

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us